Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$5.63 USD
-0.25 (-4.25%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $5.63 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EBS 5.63 -0.25(-4.25%)
Will EBS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EBS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EBS
5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost
Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?
Other News for EBS
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. ...
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential ...
Emergent BioSolutions (EBS) Explores Brincidofovir for Mpox Treatment
Emergent BioSolutions (EBS) Applauds Naloxone Accessibility in U.S. House
Emergent BioSolutions 'applauds' OTC naloxone availability in U.S. House